News

Video

Treatment Choices for Recurrent dMMR Endometrial Cancer

Author(s):

Ritu Salani, MD,Bhavana Pothuri, MD

Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.

Related Videos
2 experts in this video
2 experts in this video
Whitney Goldsberry, MD
2 expert is featured in this series.
2 expert is featured in this series.
2 experts in this video
Related Content
Rebecca Arend, MD
January 8th 2025

Multidisciplinary Collaboration Is Crucial in Managing Ocular Toxicities of Mirvetuximab Soravtansine in Gynecologic Tumors

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

Diane M. Simeone, MD; Marwan G. Fakih, MD
December 18th 2023

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

NCCN | Image using AI by: Kellie Ehrmann/MJH Life Sciences
December 23rd 2024

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer

Lunresertib Plus Camonsertib in Endometrial, Ovarian Cancer | Image Credit: © Katsyarina - stock.adobe.com
December 19th 2024

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer